RIRachel A. Bender Ignacio

Rachel A. Bender Ignacio

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rachel A. Bender Ignacio has a total of 667 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Predictors of Long COVID in Adults With Untreated Mild-to-Moderate Coronavirus Disease 2019

    by Teresa H Evering, Pooja T Saha, Carlee Moser, Nikolaus Jilg, Rachel A Bender Ignacio, Prasanna Jagannathan, Katya Corado, Kevin Wongsodirdjo, Justin Ritz, Jonathan Z Li, et al.

    Background: We evaluated risk factors for long COVID (LC) in the ACTIV-2/A5401 trial, with a focus on understanding the impact of sex. Methods: Findings were analyzed in nonhospitalized adults with coronavirus disease 2019 (COVID-19) receiving placebo within 10 days of symptoms. LC was defined as self-reporting COVID-19–related symptoms at study week 24 in a diary. Demographics and clinical variables, nasal viral RNA (vRNA), and inflammatory/coagulation markers were evaluated as predictors of LC, using modified Poisson regression models. Results: Among 545 participants enrolled in January–August 2021 with a week 24 diary, the median age at entry was 44 years, 53% were female, 13% Black, 53% Hispanic/Latino, 83% US enrolled, 15% vaccinated, and 52% severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seropositive. Seventy-four (14%) had LC (19% of female and 7% of male participants). Female sex was strongly associated with LC (adjusted risk ratio, 2.64 [95% confidence interval, 1.58–4.42]). Other predictors included US enrollment, higher total symptom score at entry, presence of symptoms at the end of the acute period (days 22–28), 28-day area under the curve of vRNA levels, and higher day 28 C-reactive protein and fibrinogen. The effect of sex persisted with adjustment for the other variables, and associations with symptoms and fibrinogen level varied by sex. Conclusions: In untreated adults with COVID-19, female sex, US enrollment, symptom and vRNA burden, and inflammatory/coagulation measures were associated with increased LC risk, with some associations varying by sex. The association with female sex was not significantly attenuated by adjustment for the assessed biomarkers. These data support sex-stratified investigations of LC, as well as a potential role of thromboinflammation. Clinical Trials Registration: ClinicalTrials.gov NCT04518410.

  • Open Access

    A Novel Injectable Drug Combination Nanoparticle Containing 3 Antiretrovirals Designed for Human Immunodeficiency Virus Treatment: A First-in-Human Trial

    by Rachel A Bender Ignacio, Christine Jonsson, Simone Perazzolo, Zachary Stephen, Brett Hanscom, Eli Burnham, Phoebe Bryson-Cahn, Claborne Youngblood, Luqi Duan, Allysson Angeldekao, et al.

    Background: Long-acting antiretroviral therapy may improve adherence and decrease stigma, yet affordable combination formulations for global usage are lacking. The TLC-ART program engineered an injectable 3-drug combination in a novel nanoparticle (DcNP) product “TLC-ART 101,” composed of lopinavir (LPV), ritonavir (RTV), and tenofovir (TVF) and 2 lipid excipients. We report safety and pharmacokinetics from this first-in-human study. Methods: Three dose cohorts of people without human immunodeficiency virus (HIV) received a single subcutaneous dose of 1.5, 3.0, or 4.0 mL in an adaptive trial of up to 64 days. LPV, RTV, and TFV were measured over time in plasma, peripheral blood mononuclear cells (PBMCs), and lymph nodes. Results: All 12 participants completed the study. One participant experienced anaphylaxis, and 4 had nonserious hypersensitivity events (rash, lip swelling, generalized pruritus). All participants had grade 1–2 injection-site reactions. At the highest dose, median LPV half-life (T1/2) was 17 days, and LPV was detectable through 2 months in most participants. RTV T1/2 was 12 hours. Plasma TFV T1/2 was 3.5 days; TFV diphosphate was detected intracellularly through 14 days. Total exposure (area under the curve) was higher in PBMCs versus plasma for all 3 drugs. Conclusions: The first human application of this novel HIV DcNP resulted in detection of LPV through 2 months and TFV up to 4 days in plasma, and no meaningful prolongation of RTV. Systemic hypersensitivity was common, and although IgE elevation was not observed, additional mechanistic understanding is required prior to further development of this DcNP pipeline. Clinical Trials Registration: NCT05850728.

  • Open Access

    How would Marie Kondo design a protocol? In favor of subtractive change in clinical trials

    by Rachel Bender Ignacio, Kathryn Rowan, Deborah Cook

    Complexities in contemporary clinical trials are frequently self-defeating relative to the goals of clinical research -namely to inform and improve care for as many patients as possible. Trials need to be rigorous, relevant, ethical, inclusive, feasible and affordable. Trials require broad access to research participation to optimize the generalizability of results and influence practice and improve outcomes for diverse populations. The degree of complexity of many clinical trials today too often restricts their conduct to academic centers or specialized research organizations where only sufficiently resourced investigators can conduct them, narrowing the populations of participants having access to trials. Limiting who conducts, delivers, and participates in trials decreases the representation of participants and threatens the generalizability of trial results to underrepresented persons. Both internal and external validity may be negatively affected.Unnecessary complexity risks recruitment and retention challenges, slows time to trial completion, and requires additional research resources, driving up costs often with unclear benefit. Delayed knowledge acquisition creates lags in evidence generation and application in practice. The benefits of health care advances are particularly slow to reach marginalized populations and those in low-and middle-income countries. Experiences during the COVID-19 pandemic provided a window into ways that trials could become simpler and more accessible. However, much of the regulatory guidance that allowed these adjustments has reverted to 'business as usual', foregoing these useful simplifications.We outline how the trials enterprise has lostthe proportionality that should inform trial complexity. Humans consistently default to additive changes and are less likely to identify opportunities for subtractive change -that is, removing components and complexity. 1 However, the 'more is more' approach runs counter to our ethical imperatives to represent relevant, diverse populations in our research, limit participant burdens, and to efficiently and economically generate impactful results. Although leading trialists have been calling for the design of large, simple trials for decades, the trend has been toward more complex procedures, rather than simplicity since then 2 . Large, simple trials are an obvious starting point for the issues we highlight here. Proportional simplicity requires retaining more stringent approaches for trials that are 'high risk' (first-in-human, vulnerable populations, high-risk interventions (e.g. chimeric antigen receptor T cells), registrational trials, or those focused on mechanistic exploration. However, even the complexity of these 'higher risk' trials needs careful review and reconsideration.The creep in trial complexity is multifactorial. Necessary protections have been added to address structural research harms that have disproportionately impacted vulnerable populations, including Black and Indigenous communities and incarcerated people, and populations in formerly colonized countries. Complexities were introduced to satisfy regulatory authorities (Food and Drug Administration (FDA), European Medicines Agency (EMA), etc.) for new drugs and devices, but are often applied across the board, including in trials of lower-risk and post-approval interventions. A vicious cycle of exhaustive data collection and monitoring, and query generation and feedback, can penalize lack of exact adherence to processes for research personnel and adds unnecessary burden for participants. This 'regulatory-industrial complex' 3 is enforced by contract research organizations (CROs) -generally for-profit companies -whose role is to execute and/or monitor trials on behalf of sponsors. There is a tipping point at which the unintended consequences of complexity jeopardize trial feasibility and affordability, especially as future research funding is likely to be further constricted in many jurisdictions.Returning to the premise that trials should be rigorous, relevant, ethical, inclusive, feasible and affordable, means that judicious subtractive change must come from funders and regulators but involve all impacted parties, especially affected communities (strategies in Table ). Trial simplification could initially focus on late-phase and post-approval studies, but be addressed for most designs, retaining more stringent approaches for trials that are 'high risk'.The 2025 E6(R3) revision to The International Council on Harmonisation (ICH) Guideline for Good Clinical Practice 4 emphasizes proportionality in trials. If implemented correctly, monitoring proportionality increases flexibility of trial designs while retaining focus on participant safety and data accuracy.Decreasing the stringency of trial procedures and processes could allow for greater participation of community and research-naïve sites, and lead to inclusion of participants outside of major medical centers. Revisions to ICH decrease emphasis on perfection, instead favoring innovations that allow flexibility to bring trials to people via remote or hybrid designs, and enable patient-collected data. Regulatory and ethics authorities, such as the FDA and EMA, national offices of human research protections, sponsors, and monitors should begin, where feasible, to integrate clinically-obtained data, allowing measurements from self-performed home vital sign monitoring, wearable physiologic devices, and blood self-collection kits.Mechanistic substudies or more complex procedures, including collection and banking of samples that require specialized processing or cryopreservation, could be limited to selected, well-resourced research sites and be optional for other sites. Protocols should allow for accredited, non-research laboratories or other standard-of-care procedures to report data without extensive re-validation. Allowing procedures to be performed locally, or remotely, or with more...

  • Top Cited Papers

    Tecovirimat for the Treatment of Mpox

    by Jason Zucker, William A. Fischer, Lu Zheng, Caitlyn McCarthy, Pooja T. Saha, Arzhang Cyrus Javan, Alex Greninger, Matthew M. Hamill, Kieron Leslie, Kristina M. Brooks, et al.

    Tecovirimat is approved for smallpox treatment under the Food and Drug Administration Animal Rule on the basis of efficacy in nonhuman primate models of mpox (previously known as monkeypox). However, the clinical efficacy of tecovirimat against human clade II mpox is unclear. In a phase 3, international, double-blind, randomized, placebo-controlled trial, we evaluated the efficacy of oral tecovirimat in adults with laboratory-confirmed clade II mpox. Participants were randomly assigned in a 2:1 ratio to receive tecovirimat or placebo for 14 days. The primary outcome was clinical resolution, assessed in a time-to-event analysis in participants with active skin or mucosal lesions. Secondary outcomes included reduction in pain, assessed in all participants with laboratory-confirmed mpox and in those with severe pain at baseline (pain score, 7 to 10; scale, 0 [no pain] to 10 [worst pain imaginable]); complete lesion healing (assessed in a time-to-event analysis); viral DNA clearance; and safety. Of 412 participants who underwent randomization (275 to tecovirimat and 137 to placebo), 344 had laboratory-confirmed mpox, and 336 had active skin or mucosal lesions and were included in the primary analysis. By day 29, the estimated cumulative incidence of clinical resolution was 83% with tecovirimat and 84% with placebo; the competing-risks hazard ratio for clinical resolution was 0.98 (95% confidence interval [CI], 0.74 to 1.31; P = 0.89). No substantial between-group differences were seen in pain reduction among participants with severe pain (difference, 0.1 point; 95% CI, -0.8 to 1.0), in complete lesion healing (competing-risks hazard ratio, 0.97; 95% CI, 0.75 to 1.26), or in viral DNA clearance. The incidence of adverse events of grade 3 or higher was similar in the two groups (4% with tecovirimat and 3% with placebo). This trial showed no evidence that tecovirimat therapy shortened the time to clinical resolution, reduced pain, or increased viral clearance among adults with clade II mpox. (Funded by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; STOMP/A5418 ClinicalTrials.gov number, NCT05534984.).


  • Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-Elicited SARS-CoV-2 Immune Responses

    by Davey M Smith, Isabelle R Weir, Sydney Ramirez, Camila H Coelho, Jennifer Manne-Goehler, Mariam Aziz, Constance A Benson, Xingye Wu, Randall Hyer, Preeti K Dhillon, et al.

    Background: How anti-SARS-CoV-2 monoclonal antibodies (mAbs) change subsequent vaccine responses remains uncertain. Methods: We conducted a prospective, phase IV, open-label study of adults who received mRNA-1273 or BNT162b2. Cohort 1 included outpatients with acute COVID-19 previously randomized to mAbs (tixagevimab/cilgavimab or amubarvimab/romlusevimab), camostat, or placebo in ACTIV-2/A5401. Cohort 2 included unvaccinated adults without reported prior COVID-19 and was analyzed as naive or non-naive by baseline neutralizing antibodies (nAbs). We measured binding IgG, nAbs, spike-specific memory B cells, and CD4+/CD8+ T cells at baseline and days 28, 56, and 140. Results: Forty-three participants were analyzed. At day 140, nAb titers were lower among prior mAb recipients and COVID-19–naive participants than among placebo/camostat recipients and those with evidence of prior infection (overall P = .018). RBD-specific, but not spike-specific, memory B cells were reduced after prior mAb therapy at days 56 and 140. Frequency of spike-specific CD4 + and CD8+ T-cell responses did not differ by prior mAb exposure. Adverse events were mostly grade 1–2 and consistent with vaccine trials. Conclusions: Prior anti-SARS-CoV-2 mAb treatment limits endogenous RBD-focused B-cell responses to later mRNA vaccination without measurably affecting T-cell immunity. Timing of vaccination after mAb therapy may matter and warrants study. Clinical Trials Registration: NCT04952402.

  • Open Access

    Genetic and environmental imprints on T cell receptor repertoires as predictors of graft-versus-host disease

    by Assya Trofimov, Zachary Montague, Magdalena L Russell, Rachel Ignacio-Bender, Terry Stevens-Ayers, Danniel Zamora, Marco Mielcarek, Michael J Boeckh, Frederick Matsen, Armita Nourmohammad

    Hematopoietic cell transplantation (HCT) as potentially curative treatment for patients with hematologic malignancies relies on T cells to mediate the potentially curative graft-versus-tumor (GVT) effect, which may be associated with graft-versus-host disease (GVHD), a potentially life-threatening complication. T cells recognize peptides presented by Human Leukocyte Antigen (HLA) molecules. It is commonly believed that matching HLA alleles between donors and recipients ensures similarity in their T cell receptor (TCR) repertoires, thereby reducing the risk of GVHD and graft rejection. However, TCR repertoires are shaped by multiple factors beyond HLA genetics, including sex, age, and immune history. The extent to which genetic variation and past infections influence TCR repertoire composition and GVHD risk remains unclear. Here, we show that while HLA haplotypes contribute to broad TCR repertoire differences, recent viral infections significantly impact TCR composition and influence GVHD risk. Analyzing 401 patients who were uniformly transplanted from healthy HLA-identical sibling HCT donors, we introduced HLA-TCR coherence, a metric that quantifies the extent to which an individual's TCR repertoire reflects their HLA haplotype. We find that higher TCR-HLA coherence is associated with greater HLA heterozygosity and an increased incidence of severe acute GVHD (grade 3-4) in transplant recipients. Furthermore, in silico identification of virus-associated TCRs (vaTCRs) using TCR sequencing and viral serology reveal specific vaTCRs predictive of either increased or decreased GVHD risk. These findings suggest that beyond HLA allele matching, donor-specific immune history and repertoire characteristics are critical determinants of GVHD risk. Thus, a more systematic integration of donor immune history may offer a complementary avenue for refining donor selection and potentially improving transplant outcomes.

  • Why Americans are Dying Younger? NIH Is Not the Problem. Our Broken Healthcare Delivery Is

    by Rachel Bender Ignacio, Jade Pagkas-Bather, Gregg Gonsalves, Sara Gianella

    The United States leads the world in biomedical innovation, with NIH-funded research driving transformative advances in cancer, HIV, and gene therapy. Yet, these breakthroughs cannot achieve their full impact in a fragmented and inequitable health system. Millions remain uninsured, preventive care is undervalued, and social determinants perpetuate life expectancy gaps. Political efforts to restrict or defund the NIH threaten progress and disproportionately harm underserved populations. Biomedical research alone cannot fix systemic failures but strengthening science while repairing care delivery systems is essential to improving population health and ensuring that innovations benefit all.

  • Why Americans are Dying Younger? NIH Is Not the Problem. Our Broken Healthcare Delivery Is

    by Rachel Bender Ignacio, Jade Pagkas-Bather, Gregg Gonsalves, Sara Gianella

    The United States leads the world in biomedical innovation, with NIH-funded research driving transformative advances in cancer, HIV, and gene therapy. Yet, these breakthroughs cannot achieve their full impact in a fragmented and inequitable health system. Millions remain uninsured, preventive care is undervalued, and social determinants perpetuate life expectancy gaps. Political efforts to restrict or defund the NIH threaten progress and disproportionately harm underserved populations. Biomedical research alone cannot fix systemic failures but strengthening science while repairing care delivery systems is essential to improving population health and ensuring that innovations benefit all.